Market & Patient Access

Market &
Patient Access

From Approval to Access.

Accelerating and optimising access to therapeutic innovation by combining global reach with deep local expertise.

By seamlessly integrating Market & Patient Access with cross-functional development capabilities, PLG supports life sciences companies in navigating complexity, shaping policy, and delivering sustainable value to healthcare systems and patients.

Achieving a successful regulatory approval is a critical milestone, but it does not guarantee patient access to your product.

In today’s complex global environment, developing a robust market access strategy is as demanding as the regulatory approval process itself. Payers, health technology assessment (HTA) bodies, and national healthcare systems require clear, compelling evidence of clinical and economic value before granting reimbursement.

In an increasingly complex and interconnected geopolitical landscape, successful pricing and reimbursement strategies demand early planning, deep local intelligence, and the ability to operate across regulatory, scientific, commercial, and policy dimensions simultaneously.

module

Shifting from transactional submissions to proactive access planning .

A major strategic liability for expanding biopharma companies is not planning for commercial access and treating it as an afterthought or a foregone conclusion. Waiting until Phase III or post registration to define your payer value proposition often results in delayed and inequitable patient access. To avoid the disappointment that comes with misaligned clinical endpoints and restrictive reimbursement criteria, sponsors require sophisticated market access strategies that begin early in clinical development and continue throughout the product life-cycle.

PLG addresses these challenges by deploying comprehensive global market access consulting services that align your clinical development programme with local commercial realities. We can advise how to strengthen your evidence package for different market archetypes and develop launch sequencing strategies to maximise your revenue. Our cross-functional teams translate complex evidence packages into compelling arguments that resonate with payers.

Backed by direct payer insights, extensive HTA experience and deep policy expertise, we help you build a resilient strategy that minimises time-to-market and secures sustainable pricing across multiple international jurisdictions

Services

Technical Capabilities Across the Access Lifecycle

Our specialised teams deliver integrated support across five core operational pillars:

Market access and pricing strategy

Strategic planning that optimizes launch sequence and pricing strategy, maximizes value.

HTA and pricing & reimbursement

Expert navigation of HTA submissions and pricing negotiations, leveraging local knowledge.

Health economics & modeling

Rigorous economic modeling and analyses that deliver compelling evidence payers need, de-risking development.

Value evidence & medical strategy

Compelling value narratives combining clinical evidence and patient perspectives that resonate with stakeholders.

Policy & advocacy

Strategic stakeholder engagement and coalition-building that shapes favorable market environments, accelerates access.

Market & Patient Access

Guillaume Bouchara

BU Managing Director

"Approval tells you a product can reach patients. Access decides whether it actually will.

Too often, the value story is written after the evidence is already fixed, and by then there is little room left to shape it.

We bring payer and HTA thinking into development early, and pair global strategy with people who know how each national system really decides.

That's how innovation becomes treatment patients can actually get."